Purpose: We designed a comprehensive multiple myeloma targeted sequencing panel to
identify common genomic abnormalities in a single assay and validated it against known …

We have previously identified the natural product obtusaquinone (OBT) as a potent
antineoplastic agent with promising in vivo activity in glioblastoma and breast cancer through the …

The benefit of autologous stem cell transplantation (ASCT) in newly diagnosed myeloma
patients, apart from supporting high dose chemotherapy, may include effects on T cell function …

Precision medicine holds great promise to improve outcomes in cancer, including
haematological malignancies. However, there are few biomarkers that influence choice of …

Introduction: Multiple myeloma (MM) is a genetically heterogeneous disease where risk
stratification and outcomes are associated with translocations involving the immunoglobulin (Ig) …

Introduction Identification of the causes of, and biomarkers for, drug resistance in myeloma
is important for understanding treatment failures, and for future instigation of targeted …

Introduction: Multiple myeloma remains an incurable disease with a significant variation in
therapeutic response. Choice of treatment is largely determined by prior lines of therapy and …

Overview: Immunotherapy has revolutionized cancer treatment. However, existing immune
checkpoint inhibitors (CPI) yield low response rates in most cancers, highlighting the need for …

Up to 50% of cancer patients are diagnosed at a late stage with tumors that are often
unresectable, leading to intensive treatments and a preventable loss of life. Whilst multiple assays …

Background Extensive protein synthesis in multiple myeloma (MM) cells renders them vulnerable
to proteasome inhibitors (PI), a cornerstone of anti-myeloma therapy. However, relapse …